{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', \"Investigator (or designee) will assess the subject's overall wellbeing, discuss compliance (if applicable), proper recording of attack details (if applicable), or\", 'any usability issues with the e-diary. A weekly phone call may be omitted if the subject records an attack as the Investigator must call and confirm or reject', 'the attack (see Footnote \"x\\').', 'f', 'An HAE medical history form will be completed by the subject at screening. Medical and medication history will be taken at screening and updated at', 'baseline.', 'g BMI calculation and height at screening; weight is to be recorded at each scheduled in-clinic visit during Part 1 except at Week 2.', 'h', 'Table 5 lists parameters to be assessed.', 'i', 'Full physical examinations will be performed at Screening, Baseline and Week 24; abbreviated physical examinations targeted to signs and symptoms will', 'be performed at all post-baseline visits except for Week 2.', 'j', 'For', 'women of childbearing potential (including adolescents), regardless of contraception or lifestyle, a serum pregnancy test will be administered at', 'screening, urinary pregnancy tests will be assessed at all subsequent visits as indicated in the table. Demonstration of a negative urine pregnancy test will be', 'required prior to the subject taking study drug on Day 1. In addition to urine pregnancy tests at study visits, women of childbearing potential who enroll at', 'sites in Europe will be dispensed urinary pregnancy tests to be completed at home at Weeks 16 and 22. Sites will confirm negative test results by telephone', 'and record the results in source documents.', 'k', 'To include blood pressure and pulse rate. Temperature and respiratory rate will be captured at Screening, Baseline and Week 24 only. Prior to obtaining vital', 'signs, subjects should rest in a supine position for at least 5 minutes.', '1', 'For women who declare that they have been post-menopausal VI 2 years.', 'm', 'A clinical diagnosis of HAE Type I or II, defined as having a C1-INH functional level below 50% and a C4 level below the lower LLN reference range, as', 'assessed during the screening period. In the absence of a low C4 value drawn during the intercritical period, 1 of the following is acceptable to confirm the', 'diagnosis of HAE assessed during the Screening period: 1) a SERPING-1 gene mutation known or likely to be associated with HAE Type 1 or 2; ;2) a', 'confirmed family history of C1-INH deficiency; 3) a C4 redrawn and retested during an attack with the results below the LLN reference range. For subjects', 'with C1-INH function > 50% but less than the assay LLN, a SERPING-1 gene mutation known or likely to be associated with HAE Type I or II assessed', 'during the screening period or a repeat C1-INH functional level < 50% will be considered acceptable for enrollment.', 'n', 'The subject will be determined as eligible for the study based upon screening evaluations and the prospective recording of HAE attacks during the run-in', 'period. The subject must have at least 2 HAE attacks during the run-in period which meet all of the following requirements: 1) the attacks must occur during', 'the run-in period (period between Screening and Baseline; minimum of 14 days and maximum of 56 days); 2) the attacks are unique, which is defined as an', 'attack that does not begin within 48 hours of the end of a previous attack; 3) the attacks must have either been treated, required medical attention or be', 'documented to cause functional impairment based on subject entry in the diary; 4) the attacks must include symptoms of swelling. Symptoms', 'of', 'swelling,', 'in', 'addition to visible swelling, may also include symptoms in the oropharyngeal or abdominal regions which are indicative of internal swelling and; 5) the', 'attacks are otherwise confirmed by the Investigator to be HAE attacks (see Footnote \"x\\').', 'A blood sample for HLA typing will be drawn at the baseline/Day 1 visit; if a blood sample is not obtained at baseline, the sample may be drawn at any time', 'during the study.', 'p', 'A blood sample for possible exploratory PG testing will be drawn at the Baseline/Day 1 visit only if consent/assent is obtained for this optional testing; if a', 'blood sample is not obtained at baseline, the sample may be drawn at any time during the study following consent obtained from the subject.', 'q', 'Bedside 12-lead ECGs will be conducted in triplicate (ie, 3 separate readings) at 1- to 5-minute intervals predose on Day 1 and Week 24, with values for this', 'visit calculated from an average of the 3 readings. All other ECGs during the study will be single assessments. Prior to obtaining an ECG, subjects should', 'rest quietly in a supine position for at least 10 minutes. ECGs should be obtained prior to any blood sampling. An ECG should be repeated for a change from', 'baseline in QTcF > 60 msec or a QTcF interval > 500 msec.', 'The EQ-5D-5L will be administered once at baseline and 1 to 2 X at the Week 4, 8, 12, 18, and 24 visits. The subject will fill out the first EQ-5D-5L at', 'baseline and on-study to describe their current health state today as instructed per the instrument. The subject will also fill out a second EQ-5D-5L', 'based', 'on', '56']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'a recollection of their health state during an average attack that they experienced since the last study visit. If the subject has not had an attack since their last', 'study visit, the subject is not required to fill out the second, attack-related EQ-5D-5L.', 'S', 'Where possible, quality of life and health outcome questionnaires should be collected as the first assessments at a visit.', 't', 'Sites will randomize eligible subjects in the IXRS at the Day 1 visit for Part 1 and at the Week 24 visit for Part 2 study drug. At Baseline, it is preferred that', 'randomization occur preferably after all Baseline assessments have been completed. Sites using a centralized pharmacy may randomize the subject the day', 'prior to the baseline and Week 24 visits.', 'u', 'The Investigator (or designee) will set up the e-diary at the Screening visit and as needed during the study; any issues (including mediocre or poor', 'compliance) warranting e-diary re-education should occur on an as-needed basis.', 'V', \"At any time the e-diary is in a subject's possession, up to the Week 48 visit, they will enter HAE attacks and relevant details and dosing information (as\", 'applicable) at least once per day.', 'W', 'Study drug should be taken at approximately the same time each day, with whichever meal is typically the largest of the day. Subjects are not required to', 'take their doses at clinic visits. Subjects will take study drug in Part 1 beginning on Day 1 and will complete Part 1 dosing on Study Day 168 (day before', 'Week 24 visit). Subjects will take Part 2 active study drug no sooner than the conclusion of the Week 24 visit on Study Day 169, after all other study', 'procedures have been completed.', 'The Investigator (or designee) will review the e-diary record of all HAE attacks that occur from Screening through Week 48 and either confirm or reject the', \"attack as an HAE attack. At least 2 attacks that occur during the run-in period must meet the requirements outlined in Footnote 'n' in order to qualify the\", 'subject to randomize in the study. For all attacks that occur, subjects will be contacted within approximately 2 business days of the end of the attack to', 'discuss the clinical characteristics of the attack, any questions the Investigator has on the entered data or to gain additional attack details not included in the', 'e-diary that the Investigator deems important to clinically evaluate the event, as applicable. This information, in conjunction with the e-diary record, will be', 'used by the Investigator to verify or reject the event recorded in the diary as an HAE attack. The e-diary data review, subject contact summary,', 'and', 'Investigator verification of the attack will be documented in the source records; the Investigator attack verification (confirmed or rejected) will also be', 'recorded.', 'y', 'PK and PD blood samples will be drawn on all subjects with no particular relationship to the timing of study drug dosing. The Investigator (or', 'designee)', \"must ensure that the time of the last dose prior to PK and PD draw is recorded in the subject's e-diary (this may also be captured in the CRF).\", '57']\n\n###\n\n", "completion": "END"}